Table 2. Experimental Anticancer Therapies Used in 298 Randomized Clinical Trials of Breast, Colorectal, and Non–Small Cell Lung Cancer Published in 7 Major Journals, 2010-2020.
| Anticancer therapy | No. (%) |
|---|---|
| Molecular inhibitor agents | 171 (57) |
| Tyrosine kinase inhibitor | 81 (27) |
| Monoclonal antibody | 67 (23) |
| CDK inhibitor | 8 (3) |
| Biosimilar | 4 (1) |
| PARP inhibitor | 5 (2) |
| PI3K inhibitor | 3 (1) |
| Other inhibitorsa | 3 (1) |
| Immune therapy agentsb | 24 (8) |
| Cytotoxic agents | 83 (28) |
| Hormonal agents | 15 (5) |
| Other agentsc | 5 (2) |
Abbreviations: CDK, cyclin-dependent kinase; PARP, poly–(adenosine diphosphate–ribose) polymerase; PI3K, phosphatidylinositol 3-kinase.
a
Other targeted inhibitors included histone deacetylase inhibitor, BRAF inhibitor, and heat shock protein inhibitor.
b
Class of immune agents: programmed cell death ligand 1 (n = 13), programmed cell death protein 1 (n = 8), cytotoxic T-lymphocyte–associated antigen 4 (n = 1), vaccine (n = 2).
c
Other agents included bisphosphonate (4) and cyclooxygenase 2 inhibitor (1).